Please login to the form below
bezlotoxumab
This page shows the latest bezlotoxumab news and features for those working in and with pharma, biotech and healthcare.
Finch’s microbiota drug for C. diff gets FDA breakthrough status
Other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) – which works by neutralising toxins secreted by the bacterium – and prophylactic
Latest news
-
Microbiome specialist Rebiotix chalks up C. diff trial success
Meanwhile, other emerging strategies for the prevention of C. diff recurrence include antibodies like Merck &Co's recently-approved Zinplava (bezlotoxumab) - which works by neutralising toxins secreted by the bacterium - and
-
After delay, Merck gets US approval for serious infection drug
2020. A marketing authorisation application for bezlotoxumab has been filed with the EMA and is also under review. ... Bezlotoxumab was originally developed by Medarex, which was acquired by Bristol-Myers Squibb in 2009.
-
Merck prepares filings for Clostridium antibody
Another antibody being developed as a combination with bezlotoxumab, actoxumab, was dropped from the study for "efficacy and safety reasons" after an interim analysis, according to Merck. ... Bezlotoxumab and actoxumab were developed in house by Merck in
-
UPDATE: Merck to acquire Cubist for $8.4bn
Actoxumab/bezlotoxumab (MK-3415A) is a combination of two antibodies in phase III development to prevent recurrence of the serious infection Clostridium difficile.
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
